OncoMatch/Clinical Trials/NCT06782555
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Is NCT06782555 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Evofosfamide and Zalifrelimab for metastatic prostate cancer.
Treatment: Evofosfamide · Zalifrelimab · Balstilimab — The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Head and Neck Squamous Cell Carcinoma
Pancreatic Cancer
Disease stage
Metastatic disease required
Histologically confirmed locally advanced or metastatic ... for which no other lines of standard therapy with demonstrated clinical benefit are available or appropriate as treatment.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
White blood cell count ≥2500 cells/mm3; Absolute neutrophil count ≥1500 cells/mm3; Absolute lymphocyte count >500 cells/mm3; Hemoglobin ≥9 g/dL; Platelets ≥75,000 cells/mm3
Kidney function
Calculated creatinine clearance ≥ 60 mL/min (by the Cockcroft Gault formula) within 7 days of Cycle 1 Day 1
Liver function
Bilirubin ≤1.5 × institutional ULN; for patients with known Gilbert's syndrome, ≤3 × institutional ULN. AST and ALT ≤3 × institutional ULN; if liver metastases are present, then ≤5 × ULN is allowed.
Adequate bone marrow function as defined by the following laboratory test results... Adequate liver function as defined by the following laboratory test results... Calculated creatinine clearance ≥ 60 mL/min (by the Cockcroft Gault formula) within 7 days of Cycle 1 Day 1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify